Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Fabrazyme
Active Ingredient: Agalsidase beta - rch 35mg
Dosage Form: Powder for infusion
New Zealand Sponsor: Medra Services Limited
Manufacturers: Genzyme Corporation, Allston, Massachusetts, United States of AmericaGenzyme Corporation, Framingham, Massachusetts, United States of America
Note: This consent is valid for two years from 24 January 2004.
Dated this 8th day of January 2004.
SUE LAURENCE, Acting Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on the 6th day of July 2001).